Drug Discovery and Development



Therapeutic Peptide Catabolite Identification using MetabolitePilot[™] 2.0 Software and the TripleTOF® 6600 System

Find, Identify and Confirm Peptide Catabolites Using MetabolitePilot[™] 2.0 Software and the Advanced Biotransform Solution

Eva Duchoslav¹, Mark Woodward², Jinal Patel¹, Suma Ramagiri and Ian Moore¹ ¹SCIEX, Concord, ON, Canada and ²Qodon Consulting LLC, Raleigh-Durham, NC, USA

Key Challenges in Peptide Catabolism Studies

- Therapeutic peptides are susceptible to unspecific proteolysis along the peptide backbone and therefore the number of potential catabolites to be considered is much larger than those from a small molecule MetID study
- In addition to unspecific cleavages potential biotransformations of the amino acids of the above species must also be considered
- Multiple charge states of both the parent peptide and potential catabolites must be considered, which increases the complexity of MetID relative to small molecule studies
- Missing, low-level peptide catabolites in complex biological matrices and incomplete catabolite information leading to repeated sample analysis and decreased productivity
- Maintaining data quality for both quantitative and qualitative analysis in a high-throughput environment

Key Features of MetabolitePilot Software for Therapeutic Peptide Catabolite Identification

- A dedicated peptide processing workflow that performs targeted searching for both hydrolytic cleavages and biotransformations for multiply charged species
- Flexible processing parameters that accommodate cross-linked and cyclic peptides plus non-natural amino acids and custom side chain modifications
- Multiple peak finding strategies utilizing MS and MS/MS information for targeted and untargeted searching for drug related metabolites for multiply charged species



Figure 1. The SCIEX Advanced Biotransform Solution featuring the new MetabolitePilotTM 2.0 software with a dedicated peptide catabolism workflow, TripleTOF® 6600 and Exion AD LC system.

- A dedicated peptide sequence assignment workspace with automated catabolite sequence generation plus candidate ranking and catabolite confirmation using a/y/b ion labelling in the MS/MS interpretation workspace
- Integrated correlation function allows comparison of catabolism across multiple samples for time course studies or inter-species comparison, using both MS and analog data.

Introduction

Even though the principles of pharmacokinetics and metabolism of small molecule drugs apply to peptide and protein drugs, the mechanisms of metabolism are very different. Small molecule drug metabolism occurs via the conversion of the molecule or moieties into more hydrophilic species via Phase I and Phase II processes. Peptide and protein drugs are acted upon by serum and tissue proteases that are distributed throughout the body and proteolysis is a major elimination pathway for most therapeutic peptides. Unmodified peptides typically have



very short half-lives. Fortunately there are many approaches available to enhance the stability of therapeutic peptides through structural modifications such as: N and C terminal protection, amino acid substitution, cyclization and amino acid modification.

Using these approaches the ADME properties of therapeutic peptides and proteins have been improved significantly and bio-therapeutic drugs have gained importance in the treatment of critical diseases. As in small molecule drug development there is a need to understand their bio-transformations to ensure that the molecule is safe and efficacious and does not cause toxicity. The ability to find, identify and confirm catabolites as quickly as possible is critical at multiple stages of drug discovery and development. Advancements in accurate mass instrumentation such as the TripleTOF® 6600 have enabled the generation of very information rich raw data but new software to automate the catabolite identification workflow is required to benefit drug metabolism researchers. To address this need SCIEX has introduced the new MetabolitePilot[™] 2.0 software that includes a dedicated peptide catabolism workflow. Figure 2 shows an overview of the data processing workflow for peptide catabolism in MetabolitePilot[™] 2.0 software. The sequence of the therapeutic peptide (including any amino acid modifications and cross links) is input into the software along with an experimental reference mass spectrum. From this data a list of potential hydrolytic cleavages is generated along with a theoretical isotope pattern, charge state range and a list of product ion and neutral losses. These pieces of data are taken along with a list of potential biotransformations to form the knowledge base used for predicted and targeted metabolite searching. In addition to targeted searching generic peak finding algorithms are also used to find unexpected metabolites. Sample to control comparisons are performed to identify new species and then the MS and

MS/MS information is used to generate a list catabolites. MetabolitePilot 2.0 software includes automated sequence generation for catabolites with rankings to speed up the data processing and an interpretation workspace for confirmation of the catabolite sequence using a/y/b fragment ion labelling of the MS/MS.

In this tech note the in-vitro metabolism of a model therapeutic peptide Bivalirudin was investigated to highlight the new peptide catabolism workflow features of MetabolitePilot 2.0 software.

Experimental

Sample Preparation

The synthetic peptide Bivalirudin (FPRPG GGGNG DFEEI PEEYL) was incubated with rat plasma at 37°C at different time points. After incubation, protein precipitation was performed with the addition of 1:1:1 acetonitrile:methanol:water 0.1% formic acid solution. The supernatant was removed and analyzed by LC/MS.

Mass Spectrometry Data Collection

A SCIEX TripleTOF® 6600 LC-MS/MS system with lonDrive[™] source was used to collect the information dependent data with dynamic background subtraction, focusing on multiply charged precursor ions. TOF MS spectra (m/z 100 to 2000) were collected with accumulation time of 150ms, the accumulation time for TOF/MS/MS (m/z 100 to 2000, CE=45, CES=15) was 75ms.

Chromatography

Samples were chromatographed on a Phenomenex Aeris 2.1 mm X 50 mm, 3 μ m column at 40°C with 6-minute gradient of eluent A, 2% acetonitrile + 0.1% formic acid, and eluent B, 98% acetonitrile + 0.1% formic acid, was




Figure 2. Data mining strategy to find degradation and catabolism products of therapeutic peptides. Therapeutic peptide sequence, its MS/MS experimental or predicted spectrum and a list of potential amino acid modifications are used as an input for series of accurate mass LC/MS peak finding strategies that find peptide – related material in either IDA or SWATH[™] data.



used at a flow rate of $400 \mu L/min.$ The injection volume was $10 \mu L$

Data Processing

The peptide specific processing parameters are shown in Figure 3. To identify therapeutic peptide–related material, a peak finding strategy based on predicted catabolites that are proteolytic hydrolysis products (minimum of 5 aa) potentially combined with a set of common modifications, such as reduction, oxidation, methylation and acetylation as well as well as any material with MS/MS fragments matching at least 2 of 6 characteristic parent peptide fragments was used. Matrix blank was used in

	Save As	Delete	Method type: I	- openeos	How Do I?
Compound Information	elect From Library	Sequence			
Compound name: Bivalirudin		1-20	FPRPGGGGNG DFEEIPEEYL		
hemical formula: C98H138N24O33					
olarity: Positive Negative					
harge state: From: 2 To: 3					
n type: [M+2H] ²⁺					
1090.5002					
	Generic Parame	ters Compound-Sp	becific Parameters		
ak Finding Strategy e this algorithm:	Catabolitas Isr	ntone Daltern Drod	uct lons and Neutral Losses		
OF MS	Consolitor in				
		Hydrolytic Cleave			
Predicted metabolites	Potential				
Generic peak finding				Min, AA count 5	
Generic peak finding Apply mass defect filter	Max. pept	tide bonds to break		Min. AA count 5	
Generis peak finding Apply mass defect filter Apply charge state filter	Max. pept	tide bonds to break: es selected: 30	1 Max. cross-links to break: 0		
Generis peak finding Apply mass defect filter Apply charge state filter Mass defect	Max. pept	tide bonds to break:		Min: AA count: 5 Neutral Formula	Neutral Mass
Generis peak finding Apply mass defect filter Apply charge state filter Mass defect	Max. pept	tide bonds to break: es selected: 30	1 Max. cross-links to break: 0		Neutral Mass
Generic peak finding Apply mass defect filter Apply charge state filter Mass defect isotope pattern	Max. pept Catabolite	tide bonds to break: ts selected: 30 AA Index	1 Max. cross-links to break: 0 Name	Neutral Formula	
Ceneric peak finding Apply mass defect filter Apply change state filter isotope pattern //f MSMS Find characteristic product ions	Max. pepl Catabolite	tide bonds to break: as selected: 30 AA Index 1:1-5	1 Max. cross-links to break: 0 Name FPRPG	Neutral Formula	572.307
Ceneric peak finding Apply mass defect filter Apply change state filter isotope pattern //f MSMS Find characteristic product ions	Max. pept Catabolity	AA Index 1:1-5 1:1-6	1 Max. cross-links to break: 0 Name FPRPG FPRPGG	Neutral Formula C27H40N8O6 C29H43N9O7	572.307 629.328
Ørener peak finding Apply mass defect filter Apply charge safe filter Apply charge safe filter Mass defect Isotop pattern Or MSMS Ørend characteristic product ions Al specified ions	Max. pept Catabolit V	tide bonds to break: as selected: 30 AA Index 1:1-5 1:1-6 1:16-20	Max. cross-links to breek: 0 Name PPRPG PPRPG PEYL	Neutral Formula C27H40N806 C29H43N907 C30H43N5011	572.307 629.328 649.295
	Max. pept Catabolity V V V	tide bonds to break: tes selected: 30 AA Index 1:1-5 1:1-6 1:16-20 1:1-7	Max. cross-links to break. 0 Name PPRPG PPRPG PEEV. FPRPGG	Neutral Formula C27H40N806 C28H43N907 C30H43N5011 C31H46N1008	572.307 629.328 649.295 686.350
	Max. pept Cataboliti V V V V	tide bonds to break: is selected: 30 AA Index 1:1-5 1:16-20 1:1-7 1:1-8	Max. cross-links to break: 0 Name PPRPAG PPRPAG PPRPAG PPRPAGG PPRPAGG PPRPAGGG PPRPAGGG	Neutral Formula C27H40NB06 C28H43N907 C30H43N5011 C31H46N1008 C33H48N1109	572.307 629.328 649.295 686.350 743.371
Conversion para fronting Apply mass offsets Apply charge state filter Apply charge state filter Mathem offset: Indiape pattern Of MGAS Water filter A A specified ions Mathematical filter Phot characteristic methanic losses A dat pose	Max. pept Cataboliti V V V V V	tide bonds to break: selected: 30 AA Index 1:1-5 1:1-6 1:1-6 1:1-7 1:1-8 1:1-520	Max cross-links to break: (0 PPRPQ PPRPQ PPRPQ PPRPQ PPRPQQ PEPYL PPRPQQQ PEEYL	Neutral Formula C27H40N806 C28H43N807 C30H43N5011 C31H46N1008 C31H46N1008 C3H48N1109 C38H54N6012	572.307 629.328 649.295 686.350 743.371 762.380
2 Conversion paral forcing 4 Apply mass office flag 4 Apply ranse softer filter 4 Apply ranse softer filter 4 Appendix Softer Softer 5 M Apple 2 Model for Softer 6 Al Apple 2 Model Softer 6 Al Apple Conversion 1 Mod Apple Softer Softer 6 Al Apple Conversion 1 Mod Apple Softer Softer 6 Al Apple Conversion 1 Model Softer 1 Model Sof	Max: pepi Cataboliti V V V V V	tide bonds to break: as selected: 30 AA index 1:1-5 1:1-6 1:1-6 1:1-7 1:1-8 1:1-5-20 1:1-9	Max cross-links to break: () Name PPRPDQ PEEVL PPRPDQG PEEVL PPRPDQGG PPRPDQGG PPRPDQGG	Neutral Formula C27H40N806 C28H43N807 C30H43N5011 C31H46N1008 C33H46N10108 C38H46N1012 C38H46N012 C37H55N13011	572 307 629 328 644 226 666 350 743 371 762 380 857 414
	Max: pept Catabolity V V V V V V V V V V V V V V V V V V V	tide bonds to break: as selected: 30 AA Index 1:1-5 1:1-6 1:1-6 1:1-7 1:1-8 1:15-20 1:1-9 1:1-9 1:14-20	Name Other PPPPQG PPPPQG PPPPQG PPPPQGG PPPPQGG PPPPQGGG PPPPQGGG PPPPQGGGG PPPPQGGGG PPPPQGGGG PPPPQGGGG PPPPQGGGGG PPPPQGGGGG PPPPQGGGGGG PPPPQGGGG PPPPQGGGGG	Neutral Formula C27H42N8006 C3H42N807 C3H43N8071 C3H44N106 C3H44N106 C3H44N107 C3H44N108 C3H44N109 C3H44N1012 C3H44N1012 C3H44N1012 C3H45N1011 C4H61N7015	572.307 629.328 649.295 6665.350 743.371 762.380 857.414 891.422

Figure 3A. The processing parameters used for Bivalirudin peak finding showing a portion of the catabolite list generated from sequential hydrolytic cleavage of the N and C terminus.

	Save As	Delete		Method typ		Constant-of	1?
Compound Information	Select From Library	Sequence					
Compound name: Bivalirudin		1-20	FPRPGGGGNG DFEE	IPEEYL			^
chemical formula: C98H138N24O33							
olarity: Positive Negative							
harge state: From: 2 To: 3							
on type: [M+2H] ²⁺							
1090.5002							
ak Finding Strategy	Generic Parameters	Compound-S	pecific Parameters				
se this algorithm:	Biotransformations	Chromatograd	phic Data MS Parameters	MS/MS Param	eters Confirmation Scoring		
TOF MS							
UP MD							
Predicted metabolites	Biotransform	ations					
Predicted metabolites	Biotransform Use this set:					Selec	t Set
Predicted metabolites Generic peak finding Apply mass defect filter	Use this set:		17			Selec	t Set
Predicted metabolites Generic peak finding Apply mass defect filter Apply charge state filter	Use this set:	Biologics	: 17			Selec	t Set
Predicted metabolites Generic peak finding Apply mass defect filter Apply charge state filter Mass defect	Use this set:	Biologics	: 17 Nome		Mess Shift	Select	t Set
Predicted metabolites Generic peak finding Apply mass defect filter Apply charge state filter Mass defect	Use this set:	Biologics					t Set
Predicted metabolites Ceneric peak finding Apply mass defect filter Apply mass defect Mass defect Isotope pattern	Use this set: Biotransforma Parent	Biologics	Name		0.0000	Description	t Set
Predicted metabolites Generic paels finding Apply mass defects filter Apply charge state filter Mass defect Isotopo pattern	Use this set: Biotransforma Parent Oxidative De	Biologics tions selected	Name		0.0000	Description Parent (P)	t Set
Predicted metabolites Predictes Predicted metabolites Predicted metabolites Predicted m	Use this set: Biotransforma Parent Oxidative De	Biologics tions selected: emination to A in and Oxidatio	Name		0.0000	Description Parent (P) R-CH2-NH2 to R-CH2-OH R-CH3 to R-CH	t Set
Ø Predicted metabolites Ø Greene paek finding Apph mass direct filter Apph charge state filter Apph charge state filter Isotope pattern TOF MSMS Ø Find characteristic product ions	Use this set: Biotransforme Parent Cixidative De Demethylatic	Biologics tions selected: amination to A in and Oxidatic xn	Name		0.0000 0.9640 1.9792	Description Parent (P) R-CH2-NH2 to R-CH2-OH R-CH3 to R-OH +2H	t Set
Ø Prodicit of methodoles Oraveria: peak indreg Apdy mass defect filter Apdy range state filter Apdy range state filter Subspe pattern TOP MGMS Ø And specified product ions Ø All specified pros Ø All specified pros	Use this set: Biotransforme Parent Cixidative De Demethylatic Hydrogenatic	Biologics tions selected: amination to A in and Oxidatic xn	Name		0.0000 0.9840 1.9792 2.0157 4.0313	Description Parent (P) R-CH2-NH2 to R-CH2-OH R-CH3 to R-OH +2H	t Set
Ø Prodicit of methodoles Oraveria: peak indreg Apdy mass defect filter Apdy range state filter Apdy range state filter Subspe pattern TOP MGMS Ø And specified product ions Ø All specified pros Ø All specified pros	Use this set: Biotransforma Parent Oxidative De Demethylatic Hydrogenatic Di-Hydrogen	Biologics tions selected: amination to A in and Oxidatic xn	Name		0.0000 0.9840 1.9792 2.0157 4.0313	Description Parent (P) R-CH2-NH2 to R-CH2-OH R-CH3 to R-OH -22H -22H -23H2 R-H to R-OH3	t Set
Production methodoles Converting and individual Apply mass official filter Apply mass official filter Apply mass official filter Mass official Individual filter Madds CPM sharesteristic productions Al specified priss Al state [2] ions Maddsset	Use this set: Biotransforme Parent Oxidative De Demethylatic Hydrogenatic Di-Hydrogen Methylation	Biologics tions selected: amination to A an and Oxidatio an ation	Name		0.0000 0.9840 1.9792 2.0157 4.0313 14.0157 15.9949	Description Parent (P) R-CH2-NH2 to R-CH2-OH R-CH3 to R-OH -22H -22H -23H2 R-H to R-OH3	
Prediction metabolities Prediction metabolities Apply mass defact filter Apply mass defact filter Apply mass defact filter Apply datage state filter Apply datage state filter Pred datasetsetistic product ions A datagetistic toris Pred characteristic neutral bases A lassert A datagetistic bases	Use this set: Biotransforme Parent Oxidative De Demethyldis DH-hydrogenatic DH-hydrogen Methylation Oxidation	Biologics tions selected: amination to A an and Oxidatio an ation	Name		0.0000 0.9840 1.9782 2.0157 4.0313 14.0157 15.9949 18.0106	Description Perent (P) R-CH2-VH2 to R-CH2-OH R-CH3 to R-CH3 to R-CH3 -2H -2H -4H to R-CH3 +0	
 Precident metabolities Precident metabolities Acyby mass defect filter Acyby mass defect filter Mass defect its filter Mass defect its filter Mass defect its filter Ad specified product lonss At least [2] ions At appecified bases At appecified bases 	Use this set Biotransforms Parent Oxidative De Demethyldic Di-Hydrogentic Di-Hydr	Biologics tions selected: amination to A an and Oxidatio an ation	Name		0.0000 0.9840 1.9782 2.0157 4.0313 14.0157 15.9849 18.0106 27.9849	Description Perent (P) R-OH2-NP42 to R-OH2-OH R-OH3 to R-OH2-OH -2H -3H -3H </td <td></td>	

Figure 3B. The processing parameters used for Bivalirudin peak finding showing a portion of the biotransfom list used in peak finding. The biotransformation list is customizable and allows deletions, additions and the creation of new biotransformations.

sample/control comparison.

Results

A total of 61 potential metabolites were found within ± 5.0 ppm and in the retention time window 0.5 to 6.0 minutes after 24 hours incubation. The catabolite with the largest peak area was the result of proteolytic cleavage at residues D-F (11,12) and has the sequence FEEI PEEYL which was assigned automatically. The retention time of the catabolite was 2.94 minutes and the retention time of the parent was 3.05 minutes, Figure 4 shows the XIC MS and MS/MS spectra of this catabolite. After identification of the catabolite in the results workspace further confirmation workspace (Figure 5). For this doubly charged catabolite 10 singly charged product ions were assigned to y or b ions within ± 4.0 ppm and this resulted in sequence coverage of 5 of 9 consecutive amino acids.




Figure 4. The results workspace of MetabolitePilot 2.0 software displaying results from the incubation of Bivalirudin with rat plasma after 24 hours. The major metabolite was found to be a result of cleavage at residues D-F (11,12) and has the sequence DFEEI PEEYL.






Figure 5. The interpret results workspace of MetabolitePilot 2.0 software displaying results of MS/MS annotation of the major metabolite DFEEI PEEYL. A total of 10 fragments peaks were assigned to b or y ions covering 5 of the 9 amino acids in the sequence.

The next two major metabolites found were methylation of the parent and methylation of the DFEEI PEEYL catabolite. These were found at retention times of 3.11 and 3.17 minutes respectively and both elute after the parent. There are 11 potential methylation sites on Bivalirudin including the N and C terminal. By matching predicted fragments of each of the putative methylation sequences to fragments in TOF MS/MS spectra of the [M+3H]3+ precursor ion, and scoring the matches, the site of modification can be proposed with confidence. MetabolitePilot assigned the most probable site of methylation to glutamic acid 14 which was supported by 22 peptide fragments which covered 10 of 20 consecutive amino acids (Figure 6). Other proteolytic cleavages were observed at residues P-R (2,3) yielding peptide RPG GGGNG DFEEI PEEYL found at retention time 2.90 minutes and P-E (16,17) yielding peptide FPRPG GGGNG DFEEI P found at 3.57 minutes.

The correlation workspace of MetabolitePilotTM 2.0 software was next used to confirm the presence of the major identified metabolites across the assay time points. The correlation workspace has an interactive graph window where results can be displayed as an x, y plot, bar graph or table. In addition to the correlation workspace overlaid XIC's, TOF MS and TOF MS/MS spectra are also displayed for the chosen metabolites/catabolites. Figure 7 displays the correlation plot of the parent, and two major metabolites found in the 5 and 24 hour samples but not in the 1 hour time point.




Figure 6. The interpret results workspace of MetabolitePilot 2.0 software displaying results of MS/MS annotation of the methylated metabolite FPRPG GGGNG DFEE[1Me]I PEEYL. A ranking of other proposed catabolites is shown in histogram format below. A total of 22 fragments peaks were assigned to b or y ions covering 10 of the 20 amino acids in the sequence.




Figure 7. The correlation workspace of MetabolitePilot 2.0 software displaying results from the incubation of Bivalirudin with rat plasma after 1, 5 and 24 hours showing the disappearance of the parent and formation of the two major maetabolies.



Conclusions

The TripleTOF™ 6600 system with new MetabolitePilot™ 2.0 software effectively addresses the complex task of performing metabolite and catabolite ID on therapeutic peptides. MetabolitePilot™ 2.0 software efficiently finds metabolites using powerful multiple peak finding strategies applied in parallel, such as non-targeted generic peak finding and targeted searching of hydrolytic cleavage catabolites and biotransformations. MetabolitePilot™ 2.0 software automatically performs catabolite sequence generation using integrated MS/MS fragment interpretation and assignment, all in a single user friendly workspace.

References

Software-Aided Workflow for Investigation of Catabolic Degradation Products During Peptide Therapeutics Compound Optimization. **Eva Duchoslav; Mark Woodward, Jinal Patel; Suma Ramagiri**. ASMS 2015 Poster Presentation. https://sciex.com/Documents/posters/asms2015_226phrama_Du choslav.pdf

AB Sciex is doing business as SCIEX.

© 2017 AB Sciex. For Research Use Only. Not for use in diagnostic procedures. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEX™ is being used under license.

Document number: RUO-MKT-02-5477



Headquarters 500 Old Connecticut Path | Framingham, MA 01701 USA Phone 508-383-7700 sciex.com International Sales For our office locations please call the division headquarters or refer to our website at sciex.com/offices